The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in the treatment of inflammatory diseases. Boehringer Ingelheim. 2002 Branger J, et al
Vermont officials said drug company payments to psychiatrists in the state averaged $45,692 EACH!, up from $20,835 in 2005; this doesn't include drug samples...